Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Action on antimicrobial resistance: It’s about time (and we’re running out)
Tamiflu review shows desperate need for full clinical trials data transparency
Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply
New materials help assess medicines policies and interventions
A new (and improved) model to regulate pharmaceutical promotion
Enhancing accountability in the medicines market: The Medicines Transparency Alliance
Bayer CEO's callous comments highlight failure of current biomedical innovation model
Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed
Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed
Regulation critical to clinical trials data transparency in Europe
When politicians go to the movies
True clinical trials transparency? Not quite, EFPIA.
Good week for access to affordable medicines
Bracing for another delay – open innovation at the WHO?
EU Policy Opportunities in Biomedical Innovation and the Public Good
Statement on Medicines Patent Pool
Public Event on EU-MERCOSUR in Buenos Aires
The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN
Conflicts of Interest and the Future of Financing for WHO.
DG Trade public hearing on the “Protection and enforcement of IPR in third countries
EU-Mercosur Trade Negotiations: What Fate for Access to medicines?
Foundations: Conlicts of interests and Democracy issues
European drug regulator challenged over revolving door case involving former Director
Corporate funding linked to EU patient & consumer groups policy